At the time of the primary analysis of overall survival ( median follow-up 184 months [ IQR 138-224 ] ) , overall survival was significantly greater in the afatinib group than in the erloinib group ( median 79 months [ 95 % CI 72-87 ] vs 68 months [ 59-78 ] ; HR 081 [ 95 % CI 069-095 ] , p = 00077 ) , as were progression-free survival ( median 26 months [ 95 % CI 20-29 ] vs 19 months [ 19-21 ] ; HR 081 [ 95 % CI 069-096 ] , p = 00103 ) and disease control ( 201 [ 51 % ] of 398 patients vs 157 [ 40 % ] of 397 ; p = 00020 ) .